« Previous
Next »
American Heart Journal
Volume 152, Issue 3
, Pages 434-441
, September 2006
Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: Rationale and design of the HEBE trial—A prospective, multicenter, randomized trial
References
- Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701–705
- Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430–436
- Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98:10344–10349
- Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg. 2002;123:1132–1140
- Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res. 2005;96:127–137
- Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004;428:668–673
- Transplantation of autologous fresh bone marrow into infarcted myocardium: a word of caution. Circulation. 2003;108(Suppl 1):II247–II252
- Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428:664–668
- . Clinical applications of stem cells for the heart. Circ Res. 2005;96:151–163
- Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913–1918
- Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. J Am Coll Cardiol. 2004;44:1690–1699
- Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation. 2003;108:2212–2218
- Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009–3017
- Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141–148
- Repair of infarcted myocardium mediated by transplanted bone marrow–derived CD34+ stem cells in a nonhuman primate model. Stem Cells. 2005;23:355–364
- Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res. 2004;95:742–748
- Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomized controlled trial. Lancet. 2006;367:113–121
- Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction—feasibility and safety. Circulation. 2005;112:I178–I183
Robin Nijveldt, MD was supported by a grant from The Netherlands Heart Foundation (2003B126).
The study is financially supported by funds provided by the ICIN, the Dutch Heart Foundation, and by unrestricted grants from Biotronik, Boston Scientific, Guerbet, Guidant, Medtronic, Novartis, Pfizer, and Sanofi-Aventis.
PII: S0002-8703(06)00133-5
doi: 10.1016/j.ahj.2006.02.007
© 2006 Mosby, Inc. All rights reserved.
« Previous
Next »
American Heart Journal
Volume 152, Issue 3
, Pages 434-441
, September 2006
